# Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer

> **NCT01042535** · PHASE1,PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 44 (actual)

## Conditions studied

- Male Breast Cancer
- Recurrent Breast Cancer
- Stage IV Breast Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** adenovirus-p53 transduced dendritic cell (DC) vaccine
- **DRUG:** 1-methyl-d-tryptophan
- **OTHER:** Laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01042535
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-28
- **Primary completion:** 2014-12-01
- **Final completion:** 2018-02-27
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2018-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01042535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01042535, "Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01042535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*